MME

Chr 3ADAR

membrane metalloendopeptidase

Also known as: CALLA, CD10, CMT2T, NEP, SCA43, SFE

The protein encoded by this gene is a type II transmembrane glycoprotein and a common acute lymphocytic leukemia antigen that is an important cell surface marker in the diagnosis of human acute lymphocytic leukemia (ALL). The encoded protein is present on leukemic cells of pre-B phenotype, which represent 85% of cases of ALL. This protein is not restricted to leukemic cells, however, and is found on a variety of normal tissues. The protein is a neutral endopeptidase that cleaves peptides at the amino side of hydrophobic residues and inactivates several peptide hormones including glucagon, enkephalins, substance P, neurotensin, oxytocin, and bradykinin. [provided by RefSeq, Aug 2017]

GeneReviewsOMIMResearchGenerating clinical summary…

Primary Disease Associations & Inheritance

?Spinocerebellar ataxia 43MIM #617018
AD
Charcot-Marie-Tooth disease, axonal, type 2TMIM #617017
ADAR

Clinical highlights

Gene-disease validity (ClinGen)
Charcot-Marie-Tooth disease type 2T · ARDefinitivesufficient evidence for diagnostic panels
6
Active trials
721
Pubs (1 yr)
P/LP submissions
P/LP missense
LOEUF
Multiple*
Mechanism· predicted
📖
GeneReview available — MME
Authoritative clinical overview · Recommended first read
Open GeneReview ↗
Some data sources returned errors (1)

gnomad: Error: Service overloaded

Population Genetics & Constraint

Constraint data not available from gnomAD.

ClinVar Variant Classifications

0 submitted variants in ClinVar

Protein Context — Lollipop Plot

MME · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Angio-Oedema Caused by Angiotensin-Converting-Enzyme Inhibitor

Bradykinin-degradating Enzymes Activities in Angiotensin-Converting Enzyme Inhibitors-associated Angioedema

RECRUITING
NCT04763577University Hospital, GrenobleStarted 2021-10-27
Assay of Bradykinin-degradating enzymes.
PreeclampsiaSevere Preeclampsia

Identification of Genes of Interest for Severe Forms of Preeclampsia

NOT YET RECRUITING
NCT07703826University Hospital, Strasbourg, FranceStarted 2026-09-01
Pancreas NeoplasmsPancreatic NeoplasmsPancreatic Cancer Metastatic

Predictive Value of Transcriptome-based OncoTreat/Oncotarget and Organoid Testing in Metastatic Pancreatic Cancer.

NOT YET RECRUITING
NCT06615830Prof. Dr. med. Dres. h.c. Jan Schmidt, MMEStarted 2026-06-01
Transthyretin AmyloidosisATTR-CMATTRv-PN

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

RECRUITING
NCT06465810AstraZenecaStarted 2024-06-25
Treatment of transthyretin (ATTR) amyloidosis in observational study setting
Metastatic Triple Negative Breast Cancer

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

ACTIVE NOT RECRUITING
NCT03330847Phase PHASE2AstraZenecaStarted 2018-03-07
Olaparib Continuous (28-Day cycle) 300 mg BD.Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).
Stomach NeoplasmsPainPostoperative

A Phase IV Randomized Trial of Maxigesic® Versus Standard Analgesia After Radical Gastrectomy

NOT YET RECRUITING
NCT07687394Phase PHASE4Yonsei UniversityStarted 2026-07-01
Acetaminophen (Newaminophen Premix)Maxigesic IV (acetaminophen/ibuprofen)